Supported by ECN 57357, the collaboration between Hospital 57357 and Dana Farber Boston Children’s Cancer and Blood Disorders Center (DFBC) has yielded a transformative pediatric oncology fellowship program and its sub-specialties, empowering trainees to drive change in their respective settings through research and innovation.

Over 28 graduates from Egypt, Africa, and Arab countries have already completed the pediatric oncology and radiotherapy fellowship programs, with the ninth cohort currently underway. Additionally, commencing in September, two new sub-specialty programs focusing on bone marrow transplant and infectious diseases in immunocompromised patients will be launched.

Hospital 57357 remains steadfast in its dedication to education, viewing investment in training and skill development as paramount. Since its inception in December 2014, the pediatric oncology fellowship training program, in collaboration with DFBC, Harvard University, has been overseen by experts in pediatric oncology from Egypt and the USA. Dr. Manal Zamzam, head of hospital 57357’s continuous education department, notes that since its inception, nine cohorts have been enrolled, with 41 current students and 27 graduates hailing from Kenya, Ethiopia, Kuwait, and Sudan. Moreover, two cohorts have successfully completed the sub-specialty radiotherapy fellowship program.

Beyond mere training, the program integrates research endeavors, requiring participants to dedicate 36 months to both training and research, culminating in a research project publication in an international scientific journal for graduation.

With an emphasis on fostering leadership and innovation, the fellowship program equips graduates to effect positive change. Through teamwork, knowledge exchange, healthcare service enhancement, and research initiation, graduates emerge as catalysts for progress.

The fellowship program’s esteemed partners include Dr. Marl Kiran, Dr. Lesley Lehman, and Dr. Liliana Gominrova from Harvard, the International Cancer Network, USA, and the Association of Friends of the National Cancer-free Initiative, AFNCI. Together, they uphold the program’s commitment to excellence and advancement in pediatric oncology.